China 2025 Measures for High-End Device Innovation

1. Key takeaways

Announcement No. 63 of 2025 is a whole-lifecycle document, not a review acceleration measure, and its measures sit alongside the two statutory channels.

• Scope of the document. The Announcement on Measures to Optimise Whole-Life-Cycle Supervision and Support High-End Device Innovation (No. 63 of 2025, issued 27 June 2025) sets measures for medical robots, high-end medical imaging, AI devices and novel biomaterials.
• The keyword is whole lifecycle, not faster review. The measures cover research, review, production and post-market stages, wider than channel optimisation.
• It connects to the two statutory channels. Article 10 of Order 47 (promulgated 26 August 2021, effective 1 October 2021) provides special approval for innovative devices and priority approval for urgent need; the measures support those channels without changing their conditions.
• The AI section turns on the change route. Whether an algorithm update is substantive determines variation or filing. Under Article 79 other changes are filed within 30 days; late filing brings a fine of RMB 10,000 to RMB 30,000 under Article 107.
• Policy implementation is already visible in the data. In 2025, 25 priority approvals were granted, up 212.5 percent, and 76 innovative devices were approved, up 17 percent (2025 Annual Report, NMPA, 24 February 2026).
• It overlaps in time with another 2025 instrument. The practice standard (Announcement No. 107 of 2025, issued 4 November 2025, effective 1 November 2026, 15 chapters and 132 articles, repealing No. 64 of 2014) requires conversion in the same cycle.

2. Legal basis

Regulations on the Supervision and Administration of Medical Devices (State Council Decree No. 739, promulgated 9 February 2021, effective 1 June 2021)

• Article 5: supervision follows risk management, whole-process control, scientific oversight and social co-governance.
• Article 14: seven categories of material, including risk analysis, technical requirements, test reports and clinical evaluation.
• Article 21: substantive changes require a variation; other changes require filing or reporting.

Opinions of the General Office of the State Council on Deepening Reform of Drug and Device Supervision (Guobanfa 2024 No. 53, issued 30 December 2024): 24 measures in five areas with two-stage objectives.

Provisions for the Administration of Medical Device Registration and Filing (SAMR Order No. 47, promulgated 26 August 2021, effective 1 October 2021)

• Article 10: special approval for innovative devices and priority approval for devices in urgent clinical need.
• Article 22: technical bodies shall establish a communication system.
• Article 28: non-clinical research scope: physicochemical, electrical safety, radiation safety, software, biological characteristics, biological material safety, sterilisation, animal studies and stability.
• Article 79: substantive changes require a variation; other changes are filed within 30 days; stated certificate matters fall within the variation scope.
• Article 107: failure to file leads to an order to correct and a fine of RMB 10,000 to RMB 30,000.

Normative and technical documents

• Announcement on Measures to Optimise Whole-Life-Cycle Supervision and Support High-End Device Innovation (No. 63 of 2025, issued 27 June 2025).
• Priority Review Catalogue of High-End Medical Devices (2025 edition), published in 2025.
• Special Review Procedure for Innovative Medical Devices (Announcement No. 83 of 2018, published 2 November 2018, effective 1 December 2018).
• Good Manufacturing Practice for Medical Devices (Announcement No. 107 of 2025, issued 4 November 2025, effective 1 November 2026): 15 chapters, 132 articles, adding quality assurance, verification and validation, and contract manufacturing; repeals No. 64 of 2014.
• Fees: domestic Class III initial registration RMB 153,600, variation RMB 50,400, renewal RMB 40,800; innovative device applications from small and micro enterprises are free.

Practical estimate. The item numbering of Announcement No. 63 follows the published text; this article works across the four fields and lifecycle stages. Provincial Class II fees differ, with some provinces publishing RMB 40,670 per registration unit.

3. Expert insights

Whole lifecycle is what separates this document from ordinary acceleration policy. Most support documents focus on review; Announcement No. 63 covers four stages, each with a corporate action and legal anchor.

The benefit is not a single speed gain but improvement at every interface; watching only review misses standards alignment upstream and conversion downstream.

Each of the four fields has a different regulatory pain point, so one preparation logic does not fit all.

Technology iterates faster than standards; the difference lies in evidence type. Robots rely on reliability and risk data, imaging on performance evaluation, AI on version control, biomaterials on long-term safety. One template across four fields is a major source of rework.

For AI devices the central question is the change route. A substantive algorithm update requires a variation under Article 21 of the regulation and Article 79; otherwise the change is filed within 30 days. Getting it wrong cuts both ways: a substantive change treated as a filing means the procedure was not followed, while failing to file brings a fine of RMB 10,000 to RMB 30,000 under Article 107. The control is a decision point in development, judging each release against intended use, algorithm function and performance.

The announcement supports the two channels rather than replacing them. Special approval rests on the core patent under Announcement No. 83, priority approval on the catalogue and urgent need under the 2025 catalogue. Announcement No. 63 changes neither entry condition; it supports four stages. The correct order is: apply the statutory conditions; assess the measures stage by stage; then combine timeline and cost. Reading it as a third channel misdirects the application, so the company obtains neither eligibility nor full benefit.

The two 2025 instruments overlap in time and must be scheduled together. Announcement No. 63 was issued on 27 June 2025 and the practice standard on 4 November 2025, effective 1 November 2026: different stages, same window. In 2025 there were 25 priority approvals, up 212.5 percent, and 76 innovative approvals, up 17 percent, so the catalogue route is expanding faster and the 2025 priority catalogue belongs in the annual strategy review. The production change is the three new chapters on quality assurance, verification and validation, and contract manufacturing and outsourcing, within 15 chapters and 132 articles. High-end device companies rely on contract development and manufacturing, and that chapter lands on how responsibility boundaries are shown. Both belong in one gap analysis aligned to 1 November 2026.

4. Practical recommendations

• Use four preparation templates, one per field, each with a distinct evidence emphasis.
• Build a change decision point into AI development, judged before each release.
• Judge the channel first and the measures second, applying Article 10 before assessing stage-by-stage support.
• Put the priority catalogue on the annual review list, re-checking entry as the catalogue is updated.
• Schedule system conversion alongside registration strategy, completing the gap analysis for 15 chapters and 132 articles before 1 November 2026.
• Separate variation from filing, with others filed within 30 days to avoid Article 107 exposure.

5. Verification checklist

• □ The text of Announcement No. 63 is held, product field confirmed.
• □ Applicable measures at each stage are assessed.
• □ Both channels are assessed separately (Announcement No. 83; Article 10).
• □ The priority catalogue is an annual review item.
• □ Algorithm version management and change classification are in place.
• □ The change test is written into change control, with filing within 30 days (Article 79).
• □ Article 107 exposure of RMB 10,000 to RMB 30,000 is in compliance guidance.
• □ Biological characterisation and material safety cover Article 28 for biomaterials.
• □ The gap analysis and conversion plan for Announcement No. 107 are scheduled for 1 November 2026.
• □ Responsibility boundaries for contract development and manufacturing are documented.
• □ Figures keep the distinction: 2025 priority 25 (up 212.5 percent), innovative 76 (up 17 percent).
• □ Fees follow RMB 153,600 initial, RMB 50,400 variation and RMB 40,800 renewal, with Class II verified provincially.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Chinese market. Our team manages NMPA Class II/III registrations and filing procedures, coordinates typetesting, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com